27439518|t|c-Src Suppresses Dendritic Cell Antitumor Activity via T Cell Ig and Mucin Protein-3 Receptor
27439518|a|The enhanced expression of T cell Ig and mucin protein-3 (TIM-3) on tumor - associated dendritic cells (DCs) attenuates antitumor effects of DNA vaccines. To identify a potential target (or targets) for reducing TIM-3 expression on tumor - associated DCs, we explored the molecular mechanisms regulating TIM-3 expression. In this study, we have identified a novel signaling pathway (c-Src → Bruton's tyrosine kinase → transcription factors Ets1, Ets2, USF1, and USF2) necessary for TIM-3 upregulation on DCs. Both IL-10 and TGF-β, which are produced in the tumor microenvironment, upregulated TIM-3 expression on DCs via this pathway. Suppressed expression of c-Src or downstream Bruton's tyrosine kinase, Ets1, Ets2, USF1, or USF2 blocked IL-10- and TGF-β - induced TIM-3 upregulation on DCs. Notably, in vivo knockdown of c-Src in mice reduced TIM-3 expression on tumor - associated DCs. Furthermore, adoptive transfer of c-Src - silenced DCs in mouse tumors enhanced the in vivo antitumor effects of immunostimulatory CpG DNA; however, TIM-3 overexpression in c-Src - silenced DCs blocked this effect. Collectively, our data reveal the molecular mechanism regulating TIM-3 expression in DCs and identify c-Src as a target for improving the efficacy of nucleic acid -mediated anticancer therapy.
27439518	0	5	c-Src	T028	C0079073
27439518	6	16	Suppresses	T169	C1260953
27439518	17	31	Dendritic Cell	T025	C0011306
27439518	32	41	Antitumor	T080	C2986475
27439518	42	50	Activity	T052	C0441655
27439518	55	84	T Cell Ig and Mucin Protein-3	T116,T123	C1120826
27439518	85	93	Receptor	T116,T192	C0597357
27439518	107	117	expression	T045	C1171362
27439518	121	150	T cell Ig and mucin protein-3	T116,T123	C1120826
27439518	152	157	TIM-3	T116,T123	C1120826
27439518	162	167	tumor	T191	C0027651
27439518	170	180	associated	T080	C0332281
27439518	181	196	dendritic cells	T025	C0011306
27439518	198	201	DCs	T025	C0011306
27439518	203	213	attenuates	T052	C0599946
27439518	214	223	antitumor	T080	C2986475
27439518	224	231	effects	T080	C1280500
27439518	235	247	DNA vaccines	T114,T121,T129	C0376613
27439518	273	279	target	T169	C1521840
27439518	284	291	targets	T169	C1521840
27439518	297	305	reducing	T080	C0392756
27439518	306	311	TIM-3	T116,T123	C1120826
27439518	312	322	expression	T045	C1171362
27439518	326	331	tumor	T191	C0027651
27439518	334	344	associated	T080	C0332281
27439518	345	348	DCs	T025	C0011306
27439518	398	403	TIM-3	T116,T123	C1120826
27439518	404	414	expression	T045	C1171362
27439518	439	449	identified	T080	C0205396
27439518	452	457	novel	T080	C0205314
27439518	458	475	signaling pathway	T044	C0037080
27439518	477	482	c-Src	T028	C0079073
27439518	485	509	Bruton's tyrosine kinase	T116,T126	C0218158
27439518	512	533	transcription factors	T116,T123	C0040648
27439518	534	538	Ets1	T116,T121,T123	C0107719
27439518	540	544	Ets2	T116,T123	C1451748
27439518	546	550	USF1	T116,T123	C1451716
27439518	556	560	USF2	T116,T123	C1447047
27439518	576	581	TIM-3	T116,T123	C1120826
27439518	582	594	upregulation	T044	C0041904
27439518	598	601	DCs	T025	C0011306
27439518	608	613	IL-10	T116,T129	C0085295
27439518	618	623	TGF-β	T116,T129,T192	C0076930
27439518	651	673	tumor microenvironment	T070	C2936626
27439518	675	686	upregulated	T044	C0041904
27439518	687	692	TIM-3	T116,T123	C1120826
27439518	693	703	expression	T045	C1171362
27439518	707	710	DCs	T025	C0011306
27439518	720	727	pathway	T044	C0037080
27439518	729	739	Suppressed	T169	C1260953
27439518	740	750	expression	T045	C1171362
27439518	754	759	c-Src	T028	C0079073
27439518	774	798	Bruton's tyrosine kinase	T116,T126	C0218158
27439518	800	804	Ets1	T116,T121,T123	C0107719
27439518	806	810	Ets2	T116,T123	C1451748
27439518	812	816	USF1	T116,T123	C1451716
27439518	821	825	USF2	T116,T123	C1447047
27439518	826	833	blocked	T169	C0332206
27439518	834	840	IL-10-	T116,T129	C0085295
27439518	845	850	TGF-β	T116,T129,T192	C0076930
27439518	853	860	induced	T169	C0205263
27439518	861	866	TIM-3	T116,T123	C1120826
27439518	867	879	upregulation	T044	C0041904
27439518	883	886	DCs	T025	C0011306
27439518	897	904	in vivo	T082	C1515655
27439518	905	914	knockdown	T063	C2350567
27439518	918	923	c-Src	T028	C0079073
27439518	927	931	mice	T015	C0025929
27439518	932	939	reduced	T080	C0392756
27439518	940	945	TIM-3	T116,T123	C1120826
27439518	946	956	expression	T045	C1171362
27439518	960	965	tumor	T191	C0027651
27439518	968	978	associated	T080	C0332281
27439518	979	982	DCs	T025	C0011306
27439518	997	1014	adoptive transfer	T061	C0376518
27439518	1018	1023	c-Src	T028	C0079073
27439518	1026	1034	silenced	T063	C2350567
27439518	1035	1038	DCs	T025	C0011306
27439518	1042	1047	mouse	T015	C0025929
27439518	1048	1054	tumors	T191	C0027651
27439518	1055	1063	enhanced	T052	C2349975
27439518	1068	1075	in vivo	T082	C1515655
27439518	1076	1085	antitumor	T080	C2986475
27439518	1086	1093	effects	T080	C1280500
27439518	1097	1114	immunostimulatory	T039	C2267003
27439518	1097	1122	immunostimulatory CpG DNA	T116	C0914670
27439518	1133	1138	TIM-3	T116,T123	C1120826
27439518	1139	1153	overexpression	T045	C1514559
27439518	1157	1162	c-Src	T028	C0079073
27439518	1165	1173	silenced	T063	C2350567
27439518	1174	1177	DCs	T025	C0011306
27439518	1178	1185	blocked	T169	C0332206
27439518	1191	1197	effect	T080	C1280500
27439518	1233	1242	molecular	T080	C1521991
27439518	1243	1252	mechanism	T169	C0441712
27439518	1253	1263	regulating	T038	C1327622
27439518	1264	1269	TIM-3	T116,T123	C1120826
27439518	1270	1280	expression	T045	C1171362
27439518	1284	1287	DCs	T025	C0011306
27439518	1301	1306	c-Src	T028	C0079073
27439518	1312	1318	target	T169	C1521840
27439518	1323	1332	improving	T080	C1272745
27439518	1337	1345	efficacy	T080	C1280519
27439518	1349	1361	nucleic acid	T114,T123	C0028606
27439518	1372	1390	anticancer therapy	T061	C0920425